Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
19.05. | BioMarin agrees to acquire Inozyme for $270m | ||
19.05. | Pharmaceutical Technology Excellence Awards 2025: Imagene | ||
19.05. | Leading with Purpose: Novotech's CEO on Diversity, Innovation, and Global Expansion | ||
16.05. | Eli Lilly strikes $1.3bn gene therapy deal with Rznomics | ||
16.05. | Newborn screening strategy needs modernising as HHS disbands advisory committee | ||
16.05. | Pharma's AI prospects get nudged into the future with EU's AI act | ||
16.05. | Trump revives plan for IRP use in US via MFN executive order | ||
16.05. | FDA approves Amneal's DHE migraine/cluster headache autoinjector | ||
16.05. | Revamping US pharma manufacturing: Trump's executive order faces industry doubts | ||
16.05. | FDA biosimilar approvals set for record-breaking year amid US pricing reforms | ||
16.05. | AGC Biologics and Quell to progress Treg cell therapy development | ||
16.05. | Are regulators keeping pace with AI adoption in clinical trials? | ||
16.05. | Pathos AI raises $365m for oncology drug development | ||
15.05. | Green chemistry: Navigating growing ESG challenges in pharma manufacturing | ||
15.05. | FDA awards BioCryst's Orladeyo NDA for paediatric HAE | ||
15.05. | Engineering the future: how robotics and automation are transforming pharmaceutical logistics | ||
15.05. | Introducing the Pharmaceutical Technology Excellence Awards 2025 | ||
15.05. | Podcast: AI and Supervised Machine Learning in Clinical Trials - Ep1 | ||
15.05. | Sanofi commits 'at least $20bn' to US manufacturing through 2030 | ||
15.05. | AbbVie expands siRNA push with $335m ADARx deal | ||
15.05. | Kaerus gains FDA designations for Fragile X syndrome treatment | ||
15.05. | Oligonucleotides: The Scottish research hub accelerating production scale up | ||
15.05. | Boehringer partners Tempus AI to enhance cancer therapy pipeline | ||
14.05. | Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies | ||
14.05. | Recipharm and PLG to support pharma companies in expediting market approval |